Ray Gerald L & Associates Ltd. increased its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 5.2% during the first quarter, according to its most recent filing with the SEC. The fund owned 169,125 shares of the biopharmaceutical company’s stock after buying an additional 8,340 shares during the period. Bristol-Myers Squibb makes up approximately 1.3% of Ray Gerald L & Associates Ltd.’s investment portfolio, making the stock its 17th largest position. Ray Gerald L & Associates Ltd.’s holdings in Bristol-Myers Squibb were worth $9,197,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Dodge & Cox purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at about $1,316,815,000. Jennison Associates LLC raised its stake in Bristol-Myers Squibb by 0.8% in the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after buying an additional 178,436 shares during the period. Norges Bank bought a new stake in Bristol-Myers Squibb during the fourth quarter worth $770,318,000. Teachers Advisors LLC raised its stake in Bristol-Myers Squibb by 10.8% in the fourth quarter. Teachers Advisors LLC now owns 3,824,604 shares of the biopharmaceutical company’s stock worth $223,510,000 after buying an additional 371,391 shares during the period. Finally, Canada Pension Plan Investment Board raised its stake in Bristol-Myers Squibb by 23.8% in the first quarter. Canada Pension Plan Investment Board now owns 3,362,609 shares of the biopharmaceutical company’s stock worth $182,859,000 after buying an additional 646,000 shares during the period. Institutional investors own 69.68% of the company’s stock.
Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.62% during trading on Friday, reaching $56.42. The company had a trading volume of 4,809,885 shares. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $60.45. The firm has a market capitalization of $92.52 billion, a price-to-earnings ratio of 20.61 and a beta of 1.17. The company’s 50-day moving average is $55.95 and its 200 day moving average is $54.96. Bristol-Myers Squibb also saw some unusual options trading activity on Thursday. Investors bought 781 put options on the stock. This represents an increase of approximately 117% compared to the average volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter last year, the business earned $0.69 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is 56.73%.
WARNING: This piece was originally reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/bristol-myers-squibb-company-nysebmy-shares-bought-by-ray-gerald-l-associates-ltd-updated-updated-updated.html.
A number of brokerages recently commented on BMY. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price objective for the company in a report on Thursday. Credit Suisse Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday. Cowen and Company set a $65.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, August 14th. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Buy” and an average price target of $62.12.
In other news, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the purchase, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.